How Did We Get Here? Antithrombotic Therapy after Bioprosthetic Aortic Valve Replacement: A Review.
Rachel EikelboomRichard P WhitlockRenato D LopesDeborah SiegalIqbal H JafferPaul DrakosSam SchulmanEmilie P Belley-CôtéPublished in: Thrombosis and haemostasis (2022)
Insufficient antithrombotic therapy after bioprosthetic aortic valve replacement has serious implications: ischemic stroke, systemic arterial thromboembolism, and clinical and subclinical valve thromboses. Unnecessarily intense antithrombotic therapy, however, increases risk of bleeding and associated morbidity and mortality. Professional bodies have used the current low-quality evidence and generated incongruent recommendations. Researchers should prioritize generating high-quality, randomized evidence evaluating the risks and benefits of antiplatelet versus anticoagulant therapy after bioprosthetic aortic valve replacement.
Keyphrases
- aortic valve replacement
- aortic valve
- aortic stenosis
- transcatheter aortic valve implantation
- atrial fibrillation
- transcatheter aortic valve replacement
- ejection fraction
- left ventricular
- mitral valve
- coronary artery disease
- randomized controlled trial
- heart failure
- double blind
- climate change
- placebo controlled
- clinical practice
- open label
- phase ii
- risk assessment
- quality improvement
- bone marrow
- phase iii